Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Research Article, J Virol Antivir Res Vol: 2 Issue: 3
Implications for Hepatitis C Treatment and Disease Progression in an HIV/HCV Co-Infected Population
| Mackenzie Cottrell2, R Chris Rathbun1, Ryan Webb1, Pete Johnson1 and Staci M Lockhart1* |
| 1College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73117, USA |
| 2Department of Experiential Education, University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma 73117, USA |
| Corresponding author : Staci M Lockhart 1110 N. Stonewall Avenue, College of Pharmacy, Room 223, Oklahoma City, Oklahoma 73117, USA Tel: 405-271-6878 (Ext: 47369); Fax: 405-271-6430 E-mail: staci-lockhart@ouhsc.edu |
| Received: August 19, 2013 Accepted: September 11, 2013 Published: September 13, 2013 |
| Citation: Cottrell M, Rathbun RC, Webb R, Johnson P, Lockhart SM, et al. (2013) Implications for Hepatitis C Treatment and Disease Progression in an HIV/HCV Co-Infected Population. J Virol Antivir Res 2:3. doi:10.4172/2324-8955.1000114 |
Abstract
Implications for Hepatitis C Treatment and Disease Progression in an HIV/HCV Co-Infected Population
Morbidity and mortality rates from chronic liver disease secondary to hepatitis C virus (HCV) have become a significant issue for HIV infected patients. U.S. Department of Health and Human Service guidelines recommend HCV treatment for all coinfected patients without decompensated liver disease. Telaprevir and boceprevir are direct-acting agents (DAAs) recently approved for HCV genotype-1 mono-infection and have demonstrated marked improvements in viral suppression when combined with peg-interferon/ribavirin as triple therapy. Identification of co-infected patients who could benefit from HCV treatment is a necessary component of quality HIV care.
